Clinical trial · Observational
A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)
A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer
NCT04871997CI-TRIAL-00061607completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- progression-free survival (PFS)
- timeFrame
- 2019.7-2022.7
- description
- the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse
Secondary outcomes (3)
- measure
- overall survival (OS)
- timeFrame
- 2019.7-2022.7
- description
- the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
- measure
- objective response rate (ORR)
- timeFrame
- 2019.7-2022.7
- description
- the percentage of patients on whom a therapy has some defined effect; for example, the cancer shrinks or disappears after treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age: ≥18 years old, no gender limit. 2. Diagnosed as advanced non-small cell lung cancer. 3. At least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm. 4. Doctors evaluate the benefits of receiving Anlotinib treatment. 5. The patient voluntarily joins the project and signs the informed consent. If any of the above items is "No", the patient is not suitable for this study. Exclusion Criteria: 1. Those who have been confirmed to be allergic to anlotinib and/or its excipients. 2. Patients with anlotinib contraindications.
References
Publications (1)
- DERIVEDWang J, Dong Y, Cao F, Ran R, Yin Y, Li Y, Fu Y, Xu Y, Kuang L, Chen G, Qu G, Li J, Luo Z, Song Q, Chen Y, Xu X, Yi T, Chu Q. Prospective Multicenter Observational Study of Anlotinib in Advanced Non-Small Cell Lung Cancer: Real-World Evidence From China. Thorac Cancer. 2026 Jun;17(11):e70306. doi: 10.1111/1759-7714.70306. PMID 42246683